- Home
- VERA
as of 02-06-2026 4:00pm EST
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 3.4B | IPO Year: | 2021 |
| Target Price: | $76.60 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.53 - $56.05 | Next Earning Date: | 02-25-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -211465000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Vera Therapeutics Inc. (VERA)
Chief Regulatory Officer
Avg Cost/Share
$50.08
Shares
10,000
Total Value
$500,767.00
Owned After
22,500
SEC Form 4
Director
Avg Cost/Share
$42.50
Shares
5,882
Total Value
$249,985.00
Owned After
5,882
SEC Form 4
Chief Regulatory Officer
Avg Cost/Share
$45.31
Shares
10,000
Total Value
$453,053.00
Owned After
22,500
SEC Form 4
Chief Regulatory Officer
Avg Cost/Share
$40.00
Shares
10,000
Total Value
$400,000.00
Owned After
22,500
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$27.82
Shares
3,864
Total Value
$107,498.03
Owned After
49,136
SEC Form 4
SVP, FINANCE, CHIEF ACCT OFFCR
Avg Cost/Share
$29.06
Shares
15,000
Total Value
$435,874.50
Owned After
47,839
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Turner William D. | VERA | Chief Regulatory Officer | Dec 15, 2025 | Sell | $50.08 | 10,000 | $500,767.00 | 22,500 | |
| ENRIGHT PATRICK G | VERA | Director | Dec 11, 2025 | Buy | $42.50 | 5,882 | $249,985.00 | 5,882 | |
| Turner William D. | VERA | Chief Regulatory Officer | Dec 8, 2025 | Sell | $45.31 | 10,000 | $453,053.00 | 22,500 | |
| Turner William D. | VERA | Chief Regulatory Officer | Dec 3, 2025 | Sell | $40.00 | 10,000 | $400,000.00 | 22,500 | |
| Carter Jason S | VERA | Chief Legal Officer | Nov 21, 2025 | Sell | $27.82 | 3,864 | $107,498.03 | 49,136 | |
| Young Joseph R | VERA | SVP, FINANCE, CHIEF ACCT OFFCR | Nov 11, 2025 | Sell | $29.06 | 15,000 | $435,874.50 | 47,839 |
Compare VERA vs Leading Stocks
See how VERA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VERA Vera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.